GHK-Cu Dosage: 180 Papers, 3 Registry Records, 0 Injection Trials

What the three registry records are

A registry search returns three entries. Opening each one settles what kind of evidence exists.

Record	Design	What it studies
NCT05932732	Phase 4, n=27, completed	Facial skin quality, hydration and barrier across three HydraFacial treatments (Austin Institute for Clinical Research)
NCT07706361	n=100, not yet recruiting	Effect of the LifeWave X39 patch on circulating GHK and GHK-Cu, sponsored by the patch manufacturer
Third entry	—	Filed by a sponsor whose registry records do not survive checking; not cited here

A cosmetic procedure and a patch. Neither administers the compound the way a dosage chart for it assumes.

Two extrapolations, not one

Most pages on this site warn about a single conversion problem: a rodent figure expressed per kilogram of animal body weight does not convert to a person. GHK-Cu carries that problem and a second one on top of it.

The second is route. The literature that gives the compound its reputation is overwhelmingly topical and in vitro: skin, wound healing, copper transport. A copper complex applied to a surface and the same complex injected are different exposures with different distribution, and no published study bridges them.

So an injection figure inherits two unquantified jumps before the arithmetic even begins, and the arithmetic will be exact regardless. Precision downstream of an unsupported input is the recurring trap in this category.

What can be stated, and what a chart should carry

What can be stated: the compound is a copper-binding tripeptide with roughly 180 PubMed records, a coherent topical literature, presence in cosmetic formulations, no approved medicinal product in any market, and no registered trial of an injected preparation.

A ghk cu dosage chart is doing honest work when it reports what topical and cosmetic studies used, in what preparation and on what tissue. It has crossed into inference the moment injection quantities appear without that context, and a table renders both the same way.

The usual input caveat also applies with full force: on a research vial the labelled mass is a seller's claim, so every figure downstream carries that error unmeasured.

Frequently Asked Questions

How many registered trials of injected GHK-Cu exist?expand_more

None. The three registry records are a completed facial skin quality study, a not yet recruiting study of a wellness patch, and one filed by a sponsor whose records do not survive checking.

Is the research base real?expand_more

Yes, around 180 PubMed records, but it is overwhelmingly topical and in vitro work on skin, wound healing and copper transport.

Why does the route matter so much here?expand_more

Because the published evidence concerns a copper complex delivered to the skin surface. Injection is a different exposure, and no study bridges the two.

Can a concentration still be calculated?expand_more

The arithmetic works and is exact given an accurate label. What is missing is an established target quantity for an injected preparation.

Is there an approved GHK-Cu product?expand_more

No medicinal approval exists in any market. It appears in cosmetic formulations and is sold separately as a research chemical.

Worked Examples — Related Compound Protocols

Apply this guide to real protocols. Each linked page includes a live reconstitution calculator and titration schedule.

BPC-157 dosage protocol

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of a larger Body Protection Compound originally isolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s [1][2]. Across more than 30 years of preclinical work, BPC-157 has been shown to accelerate the healing of tendon, ligament, muscle, bone, skin, gastrointestinal tract, and cornea through pro-angiogenic mechanisms involving VEGF receptor 2 (VEGFR2) activation, nitric oxide synthase upregulation through the Akt-eNOS axis, ERK1/2 signaling, and modulation of the dopaminergic and serotonergic systems [3][4]. Chang and colleagues demonstrated in the Journal of Applied Physiology that BPC-157 promotes tendon healing by enhancing tendon outgrowth, cell survival, and migration in tendon fibroblast cultures, and that it upregulates growth hormone receptor expression in those cells [5][6]. BPC-157 is not FDA approved and remains a research peptide. Typical research dosing is 250 to 500 mcg/day subcutaneously, with cycles of 4 to 8 weeks.

Open protocolarrow_forward

MOTS-C dosage protocol

MOTS-c (mitochondrial open reading frame of the twelve-S ribosomal RNA type c) is a 16-amino-acid peptide encoded within the 12S rRNA gene of the mitochondrial genome and discovered by Changhan Lee, Pinchas Cohen, and colleagues at USC. Unlike all other known signaling peptides, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA, making it the founding member of a class of mitochondrial-derived peptides. In the seminal Cell Metabolism 2015 paper, MOTS-c was shown to enhance glucose utilization, activate AMPK, prevent age-dependent and diet-induced insulin resistance, and reduce diet-induced obesity in mice. Subsequent work demonstrated that exercise induces MOTS-c expression and that late-life MOTS-c treatment increases physical capacity. Research subcutaneous dosing typically uses 5–10 mg two or three times per week. MOTS-c is not FDA approved; an investigational MOTS-c analog (CB4211) for non-alcoholic fatty liver disease was studied in Phase Ib trials.

Open protocolarrow_forward

References & Citations

[1]
ClinicalTrials.gov NCT05932732. Trial assessing facial skin quality, hydration and skin barrier across three HydraFacial treatments. Phase 4, 27 participants, completed; Austin Institute for Clinical Research.View source →
[2]
ClinicalTrials.gov NCT07706361. Two-part study of the effects of the X39 patch on circulating GHK and GHK-Cu levels. 100 participants, not yet recruiting; LifeWave, Inc.View source →